2BREMER K, ROTH W. Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas [J] .Tumor Diagn Ther, 1996,17(1) : 1 - 6.
3JULIA A B B, KAREN L G. Bendamustine[J]. Drugs, 2001, 61(5) :631 - 638.
4HOFFKEN K, MERKLE K, SCHONFELDER M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase Ⅱ study[J ]. J Cancer Res Clin Oneol, 1998,124(11) :627 - 632.
5PONISCH W, MITROU P S, MERKLE K, et al. A randomized multicenter study of bendamustine/prednisone versus melphalane/prednisone in the primary treatment of multiple myeloma[J]. Blood, 1999, 94(10, Suppl. 1) : 123a.
二级参考文献3
1WILLITZER H, BRAUNIGER H,ENGELMANN D. Synthese und antivirale wirksamkeit yon snbstituierten 5-ureido und 5-thioureido-benzimidazolderivaten[ J]. Pharmazie, 1978,33 ( 1 ) :30 - 38.
2VON WERNER O,KREBS D.w-[Bis-(β-chlorathyl)-amino-benzimidazolyl-(2)]-propion-bzw.-butteresauren als potentielle Cytosatatika[J].J Fur Praktische Chemie,1963,20(4):178-186.
3TEICHERT J, SOHR R, BAUMANN F. Synthesis and characterization of some new phase Ⅱ metabolites of the alkylator benda- mustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma [J]. Drug Metab Dispos, 2005, 33(7) :984 -992.
1Matt Kalaycio,MD.Bendamustine:A New Look at an Old Drug[J].Cancer.2009,1:473-479.
2Von Werner O,Krebs D.ω-[Bis-(β-chlorathyl)-amino-benzimidazolyl-(2)] -propion bzw-buttersaurenren als potentielle Cytosatatika[J].J Fur Praktische Chemie,1963,20(4):18-186.
3Jan Bergman,Peter Sand.A New Simple Procedure For Alkylation Of Nitrogen Heterocycles Using Dialkyl Oxalates And Alkoxides[J].Tetrahedron Letters,1984,25(18):1957-1960.
4Belch A, Kouroukis CT, Crump M, et al. A phase Ⅱ study of borte- zomib in mantle cell lymphoma: the National Cancer Institute of Cana- da Clinical Trials Group trial IND. 150. Ann Oncol, 2007,18 ( 1 ) : 116.
5Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in pa- tients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol, 2006,24( 13 ) :2105-2112.
6Liu S, Yuan Z, Zhang C, et al. Bortezomib-based treatment for re- lapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review. J Oncol Lett, 2012,4(2 ) :262-264.
7Ozegowski W, Krebs D. Aminosiureantagonisten. III. co-[Bis-(13-chlorithyl)-amino-benzimidazolyl-(2)]-propion- bzw. -buttersiuren als potentielle Cytostatika[J]. J ftir Praktische Chemie, 196320(3-4): 178-86.
9Alamdari HS,Pinter-Brown L,Cassarino DS,et ',tl. Severe cutaneous in- ter -face drug eruption associated with bendamustine [ J ]. Dernmtolo~" Online Jourrm] ,201 O, 16 ( 7 ) : 1.
10Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exan- them with hemor/'hagi~' plaques following bendamustinechemotherapy in a patient with B-prolymphocytie leukemia[ J]. Int J Hematol,2012,95 (3) :31I -314.
